The chronic fatigue that isn't a diagnosis — the categories under the symptom

Chronic fatigue without a clear diagnosis is one of the most common complaints in primary care and one of the most inadequately addressed. It's not that medicine doesn't know any of the causes. It's that the standard workup for fatigue — the CBC, the comprehensive metabolic panel, the TSH — identifies the dramatic versions of the conditions that cause fatigue and misses the subtle ones entirely. Normal TSH doesn't rule out thyroid dysfunction in the way most patients assume it does. Normal hemoglobin doesn't rule out iron deficiency. The threshold between "in range" and "optimized" is wide, and a lot of people live in that gap exhausted while being told they're fine.

Understanding fatigue as a symptom — not a condition — is the first reframe that matters. Fatigue is what multiple different physiological disruptions feel like from the inside. The same subjective experience can be produced by inadequate thyroid hormone at the cellular level, by iron stores too low to support mitochondrial function, by cortisol patterns disrupted by chronic stress, by glucose that isn't getting into cells efficiently, by a sleep disorder you don't know you have because you've never had a sleep study. The sensation is the same. The mechanism underneath is completely different. Treating the symptom without identifying the mechanism is why most interventions aimed at fatigue don't work.

Let's walk through the differential that the standard workup usually misses.

Subclinical thyroid dysfunction is the most common offender. A normal TSH tells you the pituitary is requesting appropriate amounts of thyroid hormone; it doesn't tell you how much active thyroid hormone is reaching cells, how efficiently it's being converted, or whether cellular thyroid receptor sensitivity is intact. Free T3 — the active form of thyroid hormone — can be low in the presence of a normal TSH, particularly in people with chronic illness, significant caloric restriction, or high stress (low T3 syndrome, sometimes called euthyroid sick syndrome). Reverse T3 can be elevated, occupying thyroid receptors without activating them, in chronic stress states. These patterns don't show up on the standard TSH-only screen. If you're exhausted and your thyroid hasn't been evaluated beyond a single TSH, you don't yet have a thyroid workup — you have a screening test.

Iron deficiency without anemia is a close second. Serum ferritin — the storage form of iron — can be critically low in the presence of a completely normal hemoglobin and hematocrit. Many labs flag ferritin as "normal" at levels that functional medicine providers consider inadequate for optimal energy metabolism. Ferritin below 30 ng/mL is common in premenopausal women and is consistently associated with fatigue, cognitive symptoms, and exercise intolerance in research literature, even when hemoglobin is normal. The reason: iron is a cofactor in mitochondrial complex IV and in other electron transport chain components, meaning low iron impairs cellular energy production directly. Running on insufficient iron is like trying to run an engine without enough oil — the gauges don't immediately red-line, but performance degrades before the warning light comes on.

Sleep apnea is one of the most consistently under-diagnosed conditions in fatigued patients. Obstructive sleep apnea fragments sleep architecture hundreds of times a night without the person being aware of waking, produces chronic sleep deprivation at the architectural level even when total hours are adequate, and is associated with significant fatigue, cognitive impairment, and metabolic disruption. It is dramatically underdiagnosed in women, who often present with atypical symptoms (insomnia, fatigue, headache) rather than the classic male presentation of loud snoring and witnessed apneas. It is underdiagnosed in lean people, who are assumed not to have it. Home sleep studies have become accessible enough that "I haven't had a sleep study" in the context of persistent fatigue is a gap that needs addressing before any other intervention is pursued.

Vitamin D inadequacy affects an estimated 40% of US adults and has a well-documented relationship with fatigue, musculoskeletal symptoms, and immune function. The mechanism isn't fully characterized, but vitamin D receptors are present in virtually every tissue including the mitochondria, and insufficiency appears to impair mitochondrial function along multiple pathways. The threshold for "sufficient" in conventional medicine (typically 20 ng/mL) is lower than the 40–60 ng/mL range that many functional providers consider optimal for symptom resolution. B12 deficiency — particularly common in vegetarians, vegans, older adults, people on metformin, and people with gut pathology — produces fatigue through disrupted neurological function and impaired red blood cell formation. Both are worth measuring and optimizing before pursuing more complex interventions.

Perimenopause is a massively underrecognized cause of fatigue in women in their late thirties and forties. The hormonal shifts of perimenopause — declining and fluctuating estrogen and progesterone, often years before the final menstrual period — affect sleep architecture, energy metabolism, thyroid function, and mood simultaneously. Many perimenopausal women present to primary care with fatigue, cognitive symptoms, and disrupted sleep and are told their hormones are "normal for their age" or given antidepressants, when the underlying issue is the hormonal transition itself. The interaction between estrogen and mitochondrial function is well-established in research: estrogen supports mitochondrial biogenesis and oxidative metabolism, and declining estrogen impairs both. Fatigue in a woman in her early forties who hasn't been evaluated for perimenopause is a clinical gap, not a complete workup.

Low-grade chronic inflammation deserves attention as a standalone driver. C-reactive protein at "normal" levels in the standard range (below 10 mg/L) can still reflect meaningful inflammatory load — high-sensitivity CRP, which has greater resolution at low levels, is a better tool. Chronic inflammation consumes energy resources, disrupts sleep architecture, impairs mitochondrial function, and produces cytokines — particularly IL-6 and TNF-alpha — that directly produce fatigue as part of sickness behavior. The downstream origins of low-grade inflammation include gut dysbiosis, visceral adiposity, food sensitivities, environmental exposures, poor sleep, and chronic psychological stress. It's not a single upstream cause; it's a state that multiple inputs maintain.

Autonomic dysfunction — specifically, impaired regulation of the balance between sympathetic and parasympathetic nervous system activity — produces fatigue through a mechanism that's underappreciated in primary care. A nervous system running chronically in sympathetic overdrive, or one that has lost the flexibility to transition between states efficiently, is metabolically costly. Heart rate variability — a measure of this flexibility — is consistently lower in chronically fatigued patients across multiple conditions. Autonomic dysfunction can coexist with otherwise normal labs and produce significant fatigue, exercise intolerance, and cognitive symptoms.

Depression-spectrum disorders need naming here because they frequently present primarily as fatigue rather than as the sadness-and-hopelessness that people expect from depression. Fatigue, hypersomnia, cognitive slowing, and anhedonia are all depression-spectrum symptoms, and in some patients they predominate over mood symptoms. This is not to say that fatigue is "really" depression — the opposite misdiagnosis (telling a patient with a physical condition that they have depression) is far more common and more harmful than the reverse. But when depression is genuinely operating, treating only the physical contributors to fatigue leaves the most important driver unaddressed.

Early autoimmune conditions — Hashimoto's thyroiditis, early lupus, early Sjogren's syndrome, early rheumatoid arthritis — can present with fatigue as the dominant or sole complaint for months to years before other diagnostic features become apparent. Standard inflammatory markers may be normal or only mildly elevated. The distinguishing workup involves antibody panels — anti-thyroid peroxidase for Hashimoto's, ANA with reflex panel for lupus and connective tissue disease, anti-Ro/La for Sjogren's — that are not part of the standard fatigue workup but should be considered in the right clinical context, particularly in young to middle-aged women.

Into this landscape the peptide and supplemental conversations enter — and here the honest framing is critical. Peptides do not fix fatigue. They are not upstream of the conditions that cause fatigue. What some of them may help support is the mitochondrial function, the hormonal environment, and the metabolic efficiency that fatigue conditions impair — but only when the underlying driver has been identified and addressed first.

NAD+ precursors — nicotinamide riboside or NMN — support cellular energy metabolism by replenishing NAD+, a coenzyme essential to mitochondrial function whose levels decline with age, stress, and chronic illness. There is meaningful human trial data for NAD+ support in metabolic contexts. In fatigue specifically, the evidence is more limited, but the mechanistic case is sound: improving NAD+ availability removes a bottleneck in cellular energy production. MOTS-c, a mitochondria-derived peptide, influences metabolic flexibility and cellular stress response; the human evidence base is early but the mechanistic direction is consistent with the mitochondrial fatigue hypothesis. Sermorelin — a growth hormone-releasing hormone analog — supports pituitary GH production, which in turn affects body composition, sleep architecture, and metabolic efficiency. For patients with documented low-normal GH axis function and fatigue as part of the picture, this is a conversation worth having with a prescribing provider after the foundational workup has been completed.

The sequence matters enormously. The foundational workup — free T3 in addition to TSH, ferritin not just hemoglobin, high-sensitivity CRP, sleep study if indicated, vitamin D and B12, hormonal evaluation appropriate to life stage, autoimmune antibody panel if indicated — precedes any peptide or supplemental conversation. Not as a formality but because the upstream cause determines whether any downstream intervention can work. Mitochondrial support doesn't restore energy if the reason for mitochondrial impairment is iron deficiency that hasn't been corrected. Growth hormone support doesn't fix fatigue if the primary driver is sleep apnea fragmenting slow-wave architecture every night.

Chronic fatigue without a diagnosis is not the same as chronic fatigue without a cause. It usually means the cause hasn't been found yet, or that it's a combination of contributors none of which individually crosses the clinical threshold for a diagnosis. Comprehensive evaluation — by a provider who approaches fatigue as a symptom requiring systematic investigation rather than a complaint requiring reassurance — is the most important thing you can do. The labs that come back normal from your internist are not the full workup. They're the beginning of one.